Acquired amegakaryocytic thrombocytopenic purpura: a review of therapeutic options

Authors

Syed Ather Hussain, Department of Internal Medicine, Rochester General Hospital, Rochester, New YorkFollow
Aneeqa Zafar, Division of Hospital Medicine, University of California San Francisco, 500 Parnassus avenue, San Francisco, California
Hafsa Faisal, Department of Internal Medicine, Rochester General Hospital, Rochester, New York
Mohammad Ammad Ud Din, Department of Internal Medicine, Rochester General Hospital, Rochester, New York

Abstract

Acquired amegakaryocytic thrombocytopenic purpura (AATP) is a rare bone marrow disorder characterized by either a marked decrease or a complete absence of megakaryocytes with preservation of all other cell lines. More than 60 cases of AATP have been reported in literature thus far. Due to the rarity of this disease, no standard treatment guidelines have been established and therapy is based on a handful of case studies and expert opinion. Herein, we provide a comprehensive review on currently utilized therapeutic options for AATP.

Recommended Citation

Hussain, Syed Ather; Zafar, Aneeqa; Faisal, Hafsa; and Din, Mohammad Ammad Ud (2023) "Acquired amegakaryocytic thrombocytopenic purpura: a review of therapeutic options," Hematology/Oncology and Stem Cell Therapy: Vol. 16 : Iss. 3 , Article 13.
Available at: https://doi.org/10.56875/2589-0646.1063

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Publisher Note

This article was previously made available with incorrect page numbers 291-302. The article has been repaginated and the article is now available with the correct page numbers for volume 16, issue 3 279-290.